BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32394054)

  • 21. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
    Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; van Schaik JH; Boonstra H; Sweep CG
    Anticancer Res; 2002; 22(1A):275-82. PubMed ID: 12017303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study.
    Dariusz S; Agnieszka M; Elzbieta R; Danuta ON; Maciej Z; Piotr D; Nowicki M
    Eur J Obstet Gynecol Reprod Biol; 2012 Aug; 163(2):193-9. PubMed ID: 22525297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.
    Eppenberger U; Kueng W; Schlaeppi JM; Roesel JL; Benz C; Mueller H; Matter A; Zuber M; Luescher K; Litschgi M; Schmitt M; Foekens JA; Eppenberger-Castori S
    J Clin Oncol; 1998 Sep; 16(9):3129-36. PubMed ID: 9738585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
    Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
    J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
    J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.
    de Witte JH; Sweep CG; Klijn JG; Grebenschikov N; Peters HA; Look MP; van Tienoven TH; Heuvel JJ; Bolt-De Vries J; Benraad TJ; Foekens JA
    Br J Cancer; 1999 Apr; 80(1-2):286-94. PubMed ID: 10390010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
    Itoh T; Hayashi Y; Kanamaru T; Morita Y; Suzuki S; Wang W; Zhou L; Rui JA; Yamamoto M; Kuroda Y; Itoh H
    J Gastroenterol Hepatol; 2000 Apr; 15(4):422-30. PubMed ID: 10824888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer.
    Fredstorp-Lidebring M; Bendahl PO; Brünner N; Casslén B; Högberg T; Långström-Einarsson E; Willén R; Fernö M
    Eur J Cancer; 2001 Dec; 37(18):2339-48. PubMed ID: 11720826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
    Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
    BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma].
    Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Horch HH
    Mund Kiefer Gesichtschir; 2004 May; 8(3):180-90. PubMed ID: 15138856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
    Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR
    Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
    Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N; Kates RE; Schmitt M
    J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.